Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Resistant dextrin is a soluble dietary fiber and prebiotic produced through the controlled heat and enzymatic treatment of starches, such as corn or wheat. Unlike standard maltodextrins, its unique glycosidic linkages allow it to resist enzymatic hydrolysis in the human small intestine, enabling the majority of the molecule to reach the large intestine intact. Once in the colon, it is fermented by commensal gut microbiota into short-chain fatty acids (SCFAs), including acetate, propionate, and butyrate. These SCFAs act as signaling molecules that trigger the release of metabolic hormones like glucagon-like peptide-1 (GLP-1) and peptide YY (PYY) through the activation of G-protein coupled receptors FFAR2 and FFAR3. Consequently, resistant dextrin plays a significant role in improving glucose homeostasis, enhancing satiety, and reducing visceral adiposity. Clinically, it is extensively investigated for its potential in managing type 2 diabetes, obesity, and metabolic syndrome.
Resistant dextrin serves as a fermentable substrate for gut microbiota, producing short-chain fatty acids (SCFAs) that activate free fatty acid receptors (FFAR2/GPR43 and FFAR3/GPR41) on enteroendocrine L-cells to stimulate GLP-1 and PYY secretion. It also delays the absorption of dietary sugars in the small intestine and improves insulin signaling pathways in the liver and adipose tissue.
1 more in the full profile.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Resistant dextrin (RD).